Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach

Ash Bullement; Mark Edmondson-Jones; Nicholas Latimer

doi:10.1186/s12885-024-12287-6

Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach

BMC Cancer. 2024 Jul 22;24(1):879. doi: 10.1186/s12885-024-12287-6.

Authors

Ash Bullement^{1

2}, Mark Edmondson-Jones^{3

4}, Nicholas Latimer^{3

5}

Affiliations

¹ Delta Hat, Nottingham, UK. [email protected].
² SCHARR, University of Sheffield, Sheffield, UK. [email protected].
³ Delta Hat, Nottingham, UK.
⁴ Population Health Sciences, University of Leicester, Leicester, UK.
⁵ SCHARR, University of Sheffield, Sheffield, UK.

No abstract available

Keywords: Cost-effectiveness; Hazard ratio; Network meta-analysis; Non-small cell lung cancer; Partitioned survival model; Proportional hazards; Survival analysis.

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / economics
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / economics
Cost-Benefit Analysis*
Humans
Immune Checkpoint Inhibitors / economics
Immune Checkpoint Inhibitors / therapeutic use
Immunotherapy* / economics
Immunotherapy* / methods
Lung Neoplasms* / drug therapy
Lung Neoplasms* / economics
Quality-Adjusted Life Years

Substances

Immune Checkpoint Inhibitors